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S U M M A R Y
Objective: The aim of this study was to determine risk factors for tuberculosis (TB) caused by multidrug-
resistant Mycobacterium tuberculosis (MDR-TB) in Oromia Region, Ethiopia.
Methods: A 6-month case–control study was performed in 2013–14. Sputum samples and standardized
questionnaire data (demographics, treatment, TB contact history, underlying disease, history of
imprisonment) were collected from cases with suspected MDR-TB aged 18 years. Sputum was
processed locally in the Oromia Public Health Laboratory using standard techniques. Data from MDR-TB
cases and TB-positive controls were compared using logistic regression analysis. For each factor, the
association with outcome variables was estimated by calculating the odds ratio (OR) together with the
95% conﬁdence interval (95% CI).
Results: Of 439 suspected MDR-TB cases, 265 had a conﬁrmed M. tuberculosis infection, of whom 88
(33%) had laboratory-conﬁrmed MDR-TB. Over two-thirds (65%) were between 18 and 39 years of age.
On multivariate analysis, an occupation of farming, known TB contact history, alcohol use, HIV infection,
previous known TB history, and previous TB treatment outcome were predictors of MDR-TB.
Conclusions: The rate of MDR-TB was high among suspected cases in the Oromia Region of Ethiopia. Local
MDR-TB detection capacity and local epidemiology studies are essential to detect MDR-TB and guide
the use of the sparse resources to optimize MDR-TB control. If TB is suspected, the presence of any of
the above factors should alert Oromia Region clinicians and public health professionals to screen for
MDR-TB.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Multidrug-resistant tuberculosis (MDR-TB) has become an
increasing threat to the global control of TB,1 as it complicates the
management and control of the disease.2–4 MDR-TB is a form of
drug-resistant TB in which Mycobacterium tuberculosis can no
longer be killed by the two best antibiotics most commonly used to
cure TB, isoniazid and rifampicin.5 Unless the individuals infected
with resistant strains of M. tuberculosis are treated appropriately,
resistant strains will continue to spread in the community,
accelerating the epidemic. The impact of MDR-TB is especially
serious in low-income countries like Ethiopia, where health* Corresponding author. Tel.: +251911928774.
E-mail address: girmamulisa30@gmail.com (G. Mulisa).
http://dx.doi.org/10.1016/j.ijid.2015.08.013
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).resources, ﬁnances, and the skilled personnel required for diagnosis
and management are limited, making containment and the
prevention of further spread more difﬁcult.6
In Africa, resistance to anti-TB drugs had been assumed to be
low.7 However, more recently, drug-resistant TB has been
recognized as a major concern.8–14 The report of large numbers
of cases of MDR-TB and extensively drug-resistant M. tuberculosis
in South Africa likely represents an unrecognized and continent-
wide epidemic rather than simply sporadic or localized outbreaks.4
Both primary and retreatment cases of MDR-TB have already
been reported in Ethiopia.15 In 2011, the Ethiopian National
Tuberculosis Control and Prevention Program reported that the
rate of MDR-TB among retreatment cases was 12% and among new
cases 1.6%.16 Facility-based studies conﬁrmed that MDR-TB indeed
represented a growing problem in Ethiopia,17–21 with an increas-
ing trend in drug resistance in retreatment cases.22ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
G. Mulisa et al. / International Journal of Infectious Diseases 39 (2015) 57–6158These rising rates of MDR-TB signal the importance of
determining the associated risk factors in Ethiopia in order to better
prioritize interventions to curb the development and spread of MDR-
TB. That study showed that previous treatment with second-line
anti-tuberculosis drugs were risk factors for the emergency of MDR-
TB. It is known that second line drugs are administered to the patient
if the case is conﬁrmed to be MDR-TB, but those study enrolled
patients who used send line drugs and see for the out come.23–29
Other reported associated factors include previous hospitalization,
having a household member with MDR-TB,30 older age (45–64
years), male sex,23 underlying health conditions like HIV infection
and diabetes mellitus,25–27 personal behaviours like alcoholism and
smoking, and poor socio-economic conditions (poverty).23,25
The aim of this study was to identify the risk factors for MDR-TB
in the Oromia Region of Ethiopia in order to better tailor MDR-TB
prevention and early intervention strategies. Oromia Regional
State was selected purposively as it has an established MDR-TB
surveillance program, is the largest state in Ethiopia in terms of
population, with an estimated population in 2011 of just over
30 million, and the landmass occupies over one third of Ethiopia.31
2. Methods
An unmatched case–control study design was employed. Data
were collected during a 6-month period from October 1, 2013 to
March 30, 2014 using a structured questionnaire at the time of
sputum collection from all cases suspected of MDR-TB over
18 years of age. Patients were categorized as suspected MDR-TB
cases if they met one or more of the following conditions: failure
after retreatment, primary treatment failure, symptomatic close
contact with a conﬁrmed MDR-TB patient, symptomatic close
contact health care workers with TB, a new TB patient who
remained sputum smear-positive after 2 months of treatment, or a
retreatment patient remaining sputum smear-positive after
3 months, based on guidelines for program and clinical manage-
ment of drug-resistant TB.32 Following laboratory assessment,
cases were then classiﬁed as conﬁrmed MDR-TB patients or as
controls, i.e., non-MDR-TB.
After obtaining verbal consent from the study participants from
the different zones of Oromia Region, a trained and experienced
laboratory technologist collected the questionnaire data and
sputum from the suspected MDR-TB cases. Sputum samples were
collected according to the national guideline for sputum collection
for the laboratory diagnosis of TB. Spot morning sputum samples
were collected aseptically in 50-ml sterile Falcon tubes and the
samples were then transported to Oromia Public Health Laboratory
using a triple packaging cold chain. Samples were processed using
standard bacteriological techniques for M. tuberculosis.33The bacteria
were detected and isolated using Ziehl–Neelsen staining, Lo¨w-
enstein–Jensen medium, and Xpert MTB/RIF. Susceptibility testing of
the isolates was done using molecular techniques with a line probe
assay (Hain Lifescience, Germany; version 2) for smear- or culture-
positive samples and low Xpert MTB/RIF-positive samples directly
from a decontaminated sample. The DNA was extracted using
Genolyse chemical version 2 and the Genolyse kit method. The Xpert
MTB/RIF system (Cepheid, GeneXpert, USA)34 was also used to
determine the susceptibility of smear- and culture-negative samples.
Data were exported from Epi Info version 3.5.1 to IBM-SPSS
version 20.0 for analysis. Bivariate conditional logistic regression
analysis was used to evaluate the association between dependent
(MDR-TB) and independent variables (age, sex, occupation,
previous treatment history, residence, underlying disease,
education status, TB patient contact history, history of imprison-
ment, etc). For each of the study factors, the association was
estimated by calculating the odds ratio (OR) together with the 95%
conﬁdence interval (95% CI). The association between MDR-TBand independent variables was considered statistically signiﬁ-
cant at a p-value of less than 0.05. Multiple logistic regression
analysis was then carried out to determine which of the
dependent variables were predictors of MDR-TB.
This study received funding support and research ethics
approval from Adama Hospital Medical College, Adama, Ethiopia,
and mentoring support from MicroResearch (http://www.
microresearch.ca).
3. Results
A total of 439 individuals with presumptive MDR-TB had
sputum samples collected during the 6-month study period and
were interviewed using the structured questionnaire for their socio-
demographic background and other risk factors. Sixty percent (265/
439) of sputum samples collected from those with suspected MDR-
TB were positive for M. tuberculosis. Of these 265 M. tuberculosis-
positive samples, 33.2% (88/265) were MDR-TB cases.
Almost two-thirds of the study participants (65.3%) were aged
between 18 and 39 years. More males than females had MDR-TB
(57% vs. 43%), and this sex difference was similar in controls (59%
vs. 41%). On univariate analysis, MDR-TB was signiﬁcantly
associated with occupation; being a farmer increased the risk of
occurrence of MDR-TB three-fold compared to an employee (OR
3.3, 95% CI 1.52– 7.55). Likewise, a lack of formal education
compared to high school certiﬁcate (OR 3.5, 95% CI 1.45– 8.43) and
rural compared to urban residence (OR 2.7, 95% CI 1.54–4.85)
increased the risk of occurrence of MDR-TB by 3.5 and 2.7 times,
respectively (Table 1). Personal behavioural factors like alcohol
use, chat chewing, concurrent chronic disease, previous TB history,
antacid use for gastritis treatment while being treated for TB, and
previous unfavourable TB treatment outcome were also signiﬁ-
cantly associated with the development of MDR-TB (Table 2).
The multiple logistic regression model indicated that occupa-
tion, known TB contact history, alcohol use, concurrent disease like
HIV/AIDS, previous known TB history, and previous TB treatment
outcome were predictors of MDR-TB (Table 3).
4. Discussion
In Oromia Region, the largest state in Ethiopia by population
and by area, the rate of MDR-TB was 33% among presumptive
MDR-TB cases. This is in contrast to the rate of 15.3% reported in
Amhara National Regional State, Ethiopia.35 The higher rate in
Oromia State may be due to differences in study participant
selection. In the present study, participants with suspected MDR-
TB were selected. A similar study conducted in India found a
prevalence of MDR-TB of 53% among patients suspected to have
MDR-TB,36 a far higher rate, possibly attributable to differences in
clinical screening quality, risk factors, case detection, and
prevalence rates of MDR-TB.
In the present study, a known TB contact history, alcohol use,
HIV infection, previous known TB history, and previous TB
treatment outcome were predictors of MDR-TB. Many of these
factors have been reported before, but several differences were
also seen. In contrast to studies conducted in China37 and several
other countries (Estonia, Latvia, Peru, Philippines, Russia, South
Africa, South Korea, and Thailand),23,24 socio-demographic factors
like sex, older age (45–64 years), and marital status did not
correlate with the occurrence of MDR-TB in Oromia Region. Of
particular note, over 40% of the MDR-TB cases were women and
women of reproductive age. This has important public health
implications for pregnancy and for their children. While the
association of MDR-TB with HIV has been reported elsewhere,25–27
it was not strongly associated in an earlier review from Ethiopia,38
or in studies from Mozambique or Iran.39,40 In this study in Oromia
Table 1







p-Value Crude OR (95% CI)
Age (in completed years) 18–39 46 (63.9) 127 (71.8) 0.24 1.5 (0.75–3.05)
40–54 16 (22.2) 29 (16.4) 1
55 10 (13.9) 21 (11.9) 0.77 1.1 (0.44–3.05)
Sex Male 50 (56.8) 104 (58.1) 0.76 1.0 (0.64–1.81)
Female 38 (43.2) 73 (41.2) 1
Marital status Single 18 (21.4) 44 (25.0) 1
Married 63 (75) 123 (69.9) 0.48 0.8 (0.19–3.36)
Others 3 (3.6) 9 (5.1) 0.77 0.6 (0.17–2.48)
Family size 6 59 (81.9) 128 (76.6) 1
>6 13 (18.1) 44 (25.6) 0.21 0.6 (0.32–1.28)
Occupation Employee 21 (23.9) 21 (12.0) 1
Housewife 24 (27.3) 34 (19.4) 0.39 1.4 (0.63–3.15)
Daily labourer 14 (15.9) 27 (15.4) 0.15 1.9 (0.79–4.67)
Farmer 18 (20.5) 61 (34.9) 0.003 3.3 (1.52–7.55)
Other 11 (12.5) 32 (18.3) 0.02 2.9 (1.16–7.25)
Educational status No formal education 13 (14.8) 48 (27.1) 0.005 3.5 (1.45–8.43)
Elementary 49 (55.7) 90 (50.8) 0.13 1.7 (0.85–3.57)
High school 19 (21.6) 20 (11.3) 1
Tertiary 7 (8.0) 19 (10.7) 0.08 2.5 (0.88–7.51)
Residence Urban 56 (70.9) 80 (54.6) 1
Rural 23 (29.1) 90 (45.4) 0.001 2.7 (1.54–4.85)
MDR-TB, multidrug-resistant tuberculosis; OR, odds ratio; CI, conﬁdence interval.
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occurrence of MDR-TB on multivariate analysis. The association
of a positive TB patient contact history seen in Oromia Region is
similar to ﬁndings in Bangladesh,41 but is in contrast to ﬁndings in
Iran.39 In Oromia Region, personal behaviours like smoking and
chat chewing were not predictors of MDR-TB on multivariate
analysis, while alcohol use was associated. Studies from India,
Lithuania, and Botswana have also shown alcohol use to be
associated with MDR-TB,42–44 but this relationship was not seen in
Nepal,26 suggesting that it may be context-related, i.e., related to
local drinking habits. In this study in Oromia, only current alcohol
use was questioned – not longstanding alcohol habits.
There are several limitations to this study. Confounding factors
like TB drug quality, drug malabsorption, and poor drug compli-
ance could not be controlled for. Furthermore the study only
focused on suspected MDR-TB cases who could produce sputum.
Suspected cases were patients with failure after retreatment,
treatment failure, symptomatic close contact with a conﬁrmedTable 2
Association of clinical and behavioural factors with MDR-TB among suspected MDR-TB
Variables Cases
Number (%)
History of imprisonment Yes 4 (5.6) 
No 67 (94.4) 
History of TB contact Yes 9 (13.0) 
No 60 (87.0) 
HIV infection Positive 17 (19.5) 
Negative 70 (80.5) 
Smoking Yes 10 (11.5) 
No 77 (88.5) 
Chronic alcohol drinker Yes 10 (11.6) 
No 76 (88.4) 
Chat chewing Yes 12 (13.8) 
No 75 (86.2) 
Chronic antacid use Yes 15 (21.4) 
No 55 (78.6) 
Previous TB history Yes 80 (90.9) 
No 8 (9.1) 
Previous TB treatment outcome Cured 7 (8.1) 
Completed 6 (7.0) 
Failure 70 (81.0) 
Defaulter 3 (3.5) 
MDR-TB, multidrug-resistant tuberculosis; OR, odds ratio; CI, conﬁdence interval.MDR-TB patient, and symptomatic close contact health care
workers with TB. New TB patients who remained sputum smear-
positive after 2 months of treatment, as well as retreatment
patients remaining sputum smear-positive after 3 months were
also included in the study. Patients not meeting these criteria and
those below the age of 18 years were excluded. Given that women
of childbearing age were well-represented among the MDR-TB
cases (43%), there may indeed be children with MDR-TB among
their close contacts. Since Oromia Region is predominately rural,
factors associated with urban MDR-TB were also not identiﬁed.
Hence generalizing these MDR-TB associated factors to all of
Ethiopia is not possible. However, these factors may apply to other
predominantly rural populations in Ethiopia and possibly those in
other nearby countries with similar cultures.
The differences and similarities between factors associated
with MDR-TB in Oromia Region compared to other countries
emphasize the importance of collecting relevant data to identify
local risk factors for MDR-TB. Studies like the one done in Oromia cases in Oromia Region, Ethiopia, April 2014
Controls
Number (%)
p-Value Crude OR (95% CI)
8 (9.2) 0.41 1.7 (0.48–5.88)
79 (90.8) 1
25 (29.8) 0.02 2.8 (1.21–6.56)
59 (70.2) 1
84 (60.4) 0.01 2.7 (1.43–5.06)
55 (39.6) 1
24 (13.6) 0.61 1.2 (0.55–2.67
152 (86.4) 1
62 (35.2) 0.001 4.1 (1.99–8.56)
114 (64.8) 1
32 (18.2) 0.35 1.4 (0.67–2.85)
144 (81.8) 1
9 (6.7) 0.003 3.8 (1.57–9.25)
126 (93.3) 1
116 (65.5) 0.001 5.2 (2.38–11.58)
61 (34.5) 1
14 (11.9) 1
31 (26.3) 0.14 0.4 (0.11–1.36)
50 (42.4) 0.03 2.8 (1.05–7.43)
23 (19.5) 0.08 0.26 (0.05–1.17)
Table 3





Crude OR (95% CI) Adjusted OR (95% CI)
Occupation Employee 21 (23.9) 21 (12.0) 1 1
Housewife 24 (27.3) 34 (19.4) 1.4 (0.63–3.15) 3.4 (0.39–9.27)
Daily labourer 14 (15.9) 27 (15.4) 1.9 (0.79–4.67) 4.3 (0.61–8.32)
Farmer 18 (20.5) 61 (34.9) 3.3 (1.52–7.55) 4.8 (1.07–11.98)
Other 11 (12.5) 32 (18.3) 2.9 (1.16–7.25) 3.5 (1.85–9.97)
Educational level No formal education 13 (14.8) 48 (27.1) 3.5 (1.45–8.43) 0.8 (0.10–6.24)
Elementary 49 (55.7) 90 (50.8) 1.7 (0.85–3.57) 0.2 (0.02–1.29)
High school 19 (21.6) 20 (11.3) 1 1
Tertiary 0.3 (0.03–2.48)
TB contact history Yes 9 (13.0) 25 (29.8) 2.8 (1.21–6.56) 6.6 (1.48–29.60)
No 60 (87.0) 59 (70.2) 1 1
Alcohol use Yes 10 (11.6) 62 (35.2) 4.1 (1.99–8.56) 2.6 (1.57–12.5)
No 76 (88.4) 114 (64.8) 1 1
Chronic antacid use Yes 15 (21.4) 9 (6.7) 3.8 (1.57–9.25) 0.2 (0.03–2.32)
No 55 (78.6) 126 (93.3) 1 1
HIV infection Positive 17 (19.5) 55 (39.6) 2.7 (1.43–5.06) 1.4 (1.03–6.71)
Negative 70 (80.5) 84 (60.4) 1 1
Previous TB history Yes 80 (90.9) 116 (65.5) 5.2 (2.38–11.58) 2.6 (1.13–6.78)
No 8 (9.1) 61 (34.5) 1 1
Previous TB treatment outcome Cured 7 (8.1) 14 (11.9) 1 1
Completed 6 (7) 31 (26.3) 0.4 (0.11–1.36) 1.3 (0.25–4.31)
Failure 70 (81) 1.50 (42.4) 2.8 (1.05–7.43) 3.5 (1.57–6.99)
Defaulter 3 (3.5) 23 (19.5) 0.26 (0.05–1.17) 0.3 (0.21–3.46)
MDR-TB, multidrug-resistant tuberculosis; OR, odds ratio; CI, conﬁdence interval.
G. Mulisa et al. / International Journal of Infectious Diseases 39 (2015) 57–6160need to be repeated on a regular basis to determine whether
factors are changing.
In conclusion, in Oromia Region in Ethiopia, on multivariate
analysis, occupation (being a farmer), known TB contact history,
alcohol use, HIV infection, previous known TB history, and previous
TB treatment outcome were predictors of MDR-TB. Many were
women of childbearing age, thus their children are at risk. With
knowledge of these risk factors, a focus on MDR-TB diagnosis and
care for TB patients with identiﬁed risks needs to be a high priority
in the TB program to help curb the MDR-TB epidemic in Oromia
Region. This study emphasizes the importance of having local
capacity for the detection of MDR-TB and the need for local
epidemiology studies so results can guide the use of the sparse
resources to optimize their impact.
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